Richmond congratulates Beam Therapeutics on the preliminary results from the first three dose levels of its ongoing Phase 1/2 study investigating a potential new therapy for Alpha-1 Antitrypsin Deficiency (AATD).

As a partner in this important research, Richmond is honoured to support work that has seen nine patients receive in-vivo base editing therapy to correct a disease-causing mutation. This marks a significant advancement in the development of gene-editing approaches for rare diseases, and Richmond looks forward to contributing to consecutive parts of this clinical trial.

Dr Ulrike Lorch, Chief Medical Director at Richmond Pharmacology, emphasised the significance of this milestone:

“This is an important step forward for patients with AATD and for applying in-vivo base editing to correct gene mutations that cause disease. Everyone involved in this collaborative effort, and most importantly the patients who came forward for this clinical trial, bring hope to people with a previously incurable disease.”

For full details, see the official Beam Therapeutics announcement.

Latest news

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

Events

BIO International Convention 2025

16-19 June 2025
Richmond Pharmacology will be attending the BIO International Convention 2025 in Boston, connecting with biotech innovators at Booth 765.
View event